

TRIMEDYNE'S CHAIRMAN INTERVIEWED BY WALLST.NET

FOR IMMEDIATE RELEASE

CONTACT: Jeff Rudner
(949) 206-1007, Ext. 2285
jrudner@trimedyne.com

June 13, 2006. – Lake Forest, CA: TRIMEDYNE, INC. (OTCBB "TMED") today announced its Chairman, Marvin P. Loeb, was interviewed by WallSt.Net. The audio interview will be posted on the WallSt.Net web site.

Dr. Loeb discussed Trimedyne's new side firing laser device, which Trimedyne recently announced will be marketed by Boston Scientific Corporation (NYSE "BSX") in the United States and by Lumenis, Ltd. throughout the rest of the world for use in conjunction with Lumenis' Holmium Lasers for holmium laser ablation of the prostate (HoLAP) in men, and he provided an overview of Trimedyne's business.

The outpatient HoLAP procedure has the potential to replace conventional surgical procedures to treat an enlarged prostate, which entail hospitalization, significant bleeding and the risk of a blood transfusion, impotence and incontinence. Trimedyne's outpatient laser procedures to treat herniated or ruptured spinal discs also have the potential to replace conventional surgery, which entails hospitalization, significant bleeding, the risk of general anesthesia and a lengthy recuperation period.

Commenting on the interview, Mr. Loeb said, "We are pleased that WallSt.Net is featuring Trimedyne on their website. We are gratified by the increased attention being paid to Trimedyne's new laser products and their market potential.

To access the audio interview, go to **http://wallst.net/audio_bin/tmed.asf**.

Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. Trimedyne has an extensive portfolio of patents covering side-firing technologies. For product, financial and other information, visit Trimedyne's website, <http://www.trimedyne.com>.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.

* * * * *